Clinical Trial Update: Perifosine in Treating Patients With Recurrent Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of perifosine in recurrent prostate cancer was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Perifosine (perifosine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-02-23